Neuralstem (AMEX:CUR) Doses patient in NSI-189 Safety Depressive Disorder Trial
March 2nd, 2011
No comments
CUR’s 1st subject was dosed (2/28/11) in a Phase Ia trial to evaluate the safety of its drug, NSI-189, Read more…
